DocGo Inc. (DCGO) Stock Analysis and Metrics

DocGo

NASDAQ: DCGO

$0.66 ▲ +0.02 (+2.82%)

At close: Jul 17, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap54.31 Mn

P/E-0.27

P/S0.18

Div. Yield0.02

ROIC (Qtr)-0.01

Total Debt (Qtr)8.27 Mn

Revenue Growth (1y) (Qtr)-21.33

Add ratio to table…

About

DocGo is leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, virtual care management and ambulance services. The company aims to democratize access to healthcare by delivering care at any address and reshaping the traditional healthcare system. Its proprietary technology platform, dedicated network of certified health professionals and robust fleet of medical response vehicles operate in all 50 states and the United Kingdom.

DocGo generates revenue through its mobile health services, virtual care management and ambulance services. The company provides services to municipalities, hospital networks and health insurance providers, often in collaboration with leading healthcare organizations via long-term relationships. Its vertically integrated approach helps elevate the quality of patient care and drive business efficiencies for its customers.

The company operates through the following segments: Mobile Health Services, Transportation Services and Corporate.

• Mobile Health Services: This segment facilitates medical care via a turnkey suite of integrated, technology-enabled solutions. It provides on-site evaluation, diagnostics, triage and treatment, including vaccines and bone density screenings, in patients' homes, workplaces and other non-traditional locations. The segment offers population health offerings and chronic disease management for underserved communities.

• Transportation Services: This segment offers digitally-enabled medical transportation solutions under the Ambulnz brand. It provides reliable, efficient transfers between clinical settings and access to clinical services, including primary and specialty care and dialysis treatments. Every vehicle is equipped with the proprietary technology platform integrated with major electronic medical record systems and ShareLink TM technology for real-time vehicle tracking.

• Corporate: This segment primarily represents shared services and personnel that support both the Transportation Services and Mobile Health Services segments. It contains operating expenses such as information technology costs, certain insurance costs, compensation costs of senior and executive leadership, and software development costs for the proprietary technology platform. None of the Company's revenues or costs of goods sold are reported within the Corporate segment.

DocGo operates in a highly competitive and fragmented industry for both technology-enabled mobile healthcare solutions and medical transportation services. It competes with small local providers and large national organizations such as DispatchHealth, Modivcare, Option Care Health, Teladoc, Amwell, Signify Health, MedArrive, Biofourmis, One Medical, Falck, Global Medical Response and Southwest Ambulance. The company's competitive advantage lies in its vertically integrated suite of services, proprietary technology platform and focus on patient-centered care outside traditional brick-and-mortar facilities.

DocGo serves a diverse customer base including municipalities, hospitals and health systems, insurers, physician practices, businesses and employers. Specific customer names mentioned include NYC Health + Hospitals, the U. S. Department of Veterans Affairs, the Indian Health Service (IHS), Martin Luther King Jr. Memorial Hospital in Los Angeles, CA and the National Health Service (NHS) in the United Kingdom. The company also works with health plans such as Elevance Health, HealthFirst, EmblemHealth, Molina, LA Care and Inland Empire Health Plan.

Investment Thesis

▲ Bull case

DocGo's core growth engine is rapidly expanding beyond initial expectations, particularly in virtual care and mobile health services, creating significant operating leverage potential. SteadyMD exceeded prior guidance with $9.5 million in Q1 revenue, representing a 38% year-over-year increase in visits and lab orders, driven by strong demand from online pharmacy partnerships for weight loss and general clinical services, which management now expects to generate $34 million to $39 million in 2026—up from the prior $25 million to $30 million estimate. This acceleration is not isolated; mobile phlebotomy is projected to achieve up to 75% growth in 2026 with home visit capacity increasing from 600 to 900 per day by year-end, supported by new operations in Upstate New York, Pennsylvania, and Florida, including the recent PTI Health launch in Southern Florida leveraging major national lab integrations. Remote patient monitoring contributed over $4.1 million in Q1 with segment margins exceeding 60%, making it the highest-margin non-SteadyMD Mobile Health contributor. CareGap services have assigned over 1.6 million lives since inception with 46% year-over-year growth in completed visits and over 1,000 patients now actively managed in PCP and longitudinal care programs, targeting breakeven in late 2026. Collectively, these Mobile Health initiatives—SteadyMD, mobile phlebotomy, remote patient monitoring, and CareGap—are creating an integrated 'care anywhere' ecosystem where virtual visits drive in-home service demand, enhancing cross-selling opportunities and margin expansion as scale increases. The 24% year-over-year non-migrant revenue growth in Q1, excluding the wind-down of migrant projects, confirms organic momentum across all core segments, with Medical Transportation achieving its highest quarterly revenue ever at $51.9 million due to wins in New York, Texas, Tennessee, and the UK’s Great Western Hospitals NHS Foundation Trust. Management raised full-year 2026 revenue guidance to $300 million–$315 million from $290 million–$310 million based on Q1 outperformance and sustained volume trends, while maintaining EBITDA loss guidance at $5 million–$10 million, implying that incremental revenue will flow substantially to the bottom line as temporary margin pressures ease. Sequential declines in adjusted operating expenses (excluding depreciation, stock-based compensation, and non-recurring items) to $34.1 million from $35.7 million sequentially demonstrate early success of cost-cutting initiatives, with further SG&A reductions anticipated over the next three quarters as vendor contract changes and headcount resolutions take full effect by Q3 2026. The ongoing strategic alternatives review, while uncertain, presents a potential catalyst for valuation re-rating or structural transformation if it leads to a strategic partnership, divestiture of non-core assets, or operational restructuring that unlocks hidden value, particularly given the company’s strong cash position of $59.9 million and improving working capital trends following the April 1 receipt of $8 million in delayed migrant-related receivables.

DocGo's core growth engine is rapidly expanding beyond initial expectations, particularly in virtual care and mobile health services, creating significant operating leverage potential. SteadyMD exceeded prior guidance with $9.5 million in Q1 revenue, representing a 38% year-over-year increase in visits and lab orders, driven by strong demand from online pharmacy partnerships for weight loss and general clinical services, which management now expects to generate $34 million to $39 million in 2026—up from the prior $25 million to $30 million estimate. This acceleration is not isolated; mobile phlebotomy is projected to achieve up to 75% growth in 2026 with home visit capacity increasing from 600 to 900 per day by year-end, supported by new operations in Upstate New York, Pennsylvania, and Florida, including the recent PTI Health launch in Southern Florida leveraging major national lab integrations. Remote patient monitoring contributed over $4.1 million in Q1 with segment margins exceeding 60%, making it the highest-margin non-SteadyMD Mobile Health contributor. CareGap services have assigned over 1.6 million lives since inception with 46% year-over-year growth in completed visits and over 1,000 patients now actively managed in PCP and longitudinal care programs, targeting breakeven in late 2026. Collectively, these Mobile Health initiatives—SteadyMD, mobile phlebotomy, remote patient monitoring, and CareGap—are creating an integrated 'care anywhere' ecosystem where virtual visits drive in-home service demand, enhancing cross-selling opportunities and margin expansion as scale increases. The 24% year-over-year non-migrant revenue growth in Q1, excluding the wind-down of migrant projects, confirms organic momentum across all core segments, with Medical Transportation achieving its highest quarterly revenue ever at $51.9 million due to wins in New York, Texas, Tennessee, and the UK’s Great Western Hospitals NHS Foundation Trust. Management raised full-year 2026 revenue guidance to $300 million–$315 million from $290 million–$310 million based on Q1 outperformance and sustained volume trends, while maintaining EBITDA loss guidance at $5 million–$10 million, implying that incremental revenue will flow substantially to the bottom line as temporary margin pressures ease. Sequential declines in adjusted operating expenses (excluding depreciation, stock-based compensation, and non-recurring items) to $34.1 million from $35.7 million sequentially demonstrate early success of cost-cutting initiatives, with further SG&A reductions anticipated over the next three quarters as vendor contract changes and headcount resolutions take full effect by Q3 2026. The ongoing strategic alternatives review, while uncertain, presents a potential catalyst for valuation re-rating or structural transformation if it leads to a strategic partnership, divestiture of non-core assets, or operational restructuring that unlocks hidden value, particularly given the company’s strong cash position of $59.9 million and improving working capital trends following the April 1 receipt of $8 million in delayed migrant-related receivables.

▼ Bear case

DocGo faces persistent and underappreciated margin pressures that could prevent profitability improvement despite revenue growth, driven by structural labor cost inflation and geographic exposure to volatile fuel prices. Adjusted EBITDA worsened to a $10.2 million loss in Q1 2026 from $3.9 million in Q1 2025, even as revenue ex-migrant projects grew 24%, indicating that incremental revenue is not translating to profitability due to rising operating costs. Management explicitly cited clinician incentives at SteadyMD as negatively impacting consolidated gross margin by approximately 60 basis points, a direct result of aggressive hiring to meet unanticipated demand growth—a trend noted as a persistent constraint rather than a temporary inefficiency. Fuel costs, which rose from $2.93 to $3.69 per gallon between January and March 2026, are estimated to cost 35 basis points of consolidated gross margin per $1 increase at the pump, with average Q2 prices remaining at elevated levels and creating a continued near-term drag on gross margin that management acknowledges will persist beyond Q2 due to geopolitical instability in the Middle East. Medical Transportation gross margins remain restrained by higher-than-planned effective hourly wages for field labor, and while overtime rates improved toward sub-10% levels in Q1, this reflects ongoing wage inflation pressures that are unlikely to reverse given competitive labor markets for certified health professionals. The company’s reliance on leased-hour arrangements—where clients pay a fixed hourly rate rather than per trip—limits its ability to pass through fuel cost increases mid-contract, meaning margin recovery depends solely on volume growth or future contract renegotiations, which may not occur swiftly enough to offset current headwinds. Working capital pressure is a tangible and growing risk, with total cash and cash equivalents declining to $59.9 million at quarter end due to delayed collections on migrant-related receivables from New York City’s Department of Housing Preservation and Development; although $8 million was received on April 1, approximately $13 million remains outstanding, and management admits difficulty predicting exact timing, creating ongoing liquidity uncertainty that could constrain growth investments or force unfavorable financing terms. Adjusted gross margin decreased to 31.6% from 32.1% year-over-year, and even when stripping out migrant and SteadyMD impacts, the underlying business margin improved only marginally to 31.9% from 30.4%, suggesting limited intrinsic pricing power or operational efficiency gains. Sequential SG&A declines are anticipated but not yet realized in the income statement, with cost-cutting decisions from late Q4 and early 2026 not expected to meaningfully impact results until Q2, meaning near-term expense levels remain elevated relative to revenue growth. The strategic alternatives process, while presented as a potential upside, introduces significant uncertainty and distraction, with no assurance of outcome and potential for value-destructive outcomes if management pursues dilutive transactions or overpays for acquisitions amid pressure to show progress. Finally, the company’s guidance assumes profitability improvement in the second half of 2026, but this depends on multiple uncertain variables—fuel price stabilization, labor market normalization, timely receivables collections, and successful execution of cost-saving initiatives—any of which could fail to materialize, leaving DocGo structurally unprofitable despite revenue expansion.

DocGo faces persistent and underappreciated margin pressures that could prevent profitability improvement despite revenue growth, driven by structural labor cost inflation and geographic exposure to volatile fuel prices. Adjusted EBITDA worsened to a $10.2 million loss in Q1 2026 from $3.9 million in Q1 2025, even as revenue ex-migrant projects grew 24%, indicating that incremental revenue is not translating to profitability due to rising operating costs. Management explicitly cited clinician incentives at SteadyMD as negatively impacting consolidated gross margin by approximately 60 basis points, a direct result of aggressive hiring to meet unanticipated demand growth—a trend noted as a persistent constraint rather than a temporary inefficiency. Fuel costs, which rose from $2.93 to $3.69 per gallon between January and March 2026, are estimated to cost 35 basis points of consolidated gross margin per $1 increase at the pump, with average Q2 prices remaining at elevated levels and creating a continued near-term drag on gross margin that management acknowledges will persist beyond Q2 due to geopolitical instability in the Middle East. Medical Transportation gross margins remain restrained by higher-than-planned effective hourly wages for field labor, and while overtime rates improved toward sub-10% levels in Q1, this reflects ongoing wage inflation pressures that are unlikely to reverse given competitive labor markets for certified health professionals. The company’s reliance on leased-hour arrangements—where clients pay a fixed hourly rate rather than per trip—limits its ability to pass through fuel cost increases mid-contract, meaning margin recovery depends solely on volume growth or future contract renegotiations, which may not occur swiftly enough to offset current headwinds. Working capital pressure is a tangible and growing risk, with total cash and cash equivalents declining to $59.9 million at quarter end due to delayed collections on migrant-related receivables from New York City’s Department of Housing Preservation and Development; although $8 million was received on April 1, approximately $13 million remains outstanding, and management admits difficulty predicting exact timing, creating ongoing liquidity uncertainty that could constrain growth investments or force unfavorable financing terms. Adjusted gross margin decreased to 31.6% from 32.1% year-over-year, and even when stripping out migrant and SteadyMD impacts, the underlying business margin improved only marginally to 31.9% from 30.4%, suggesting limited intrinsic pricing power or operational efficiency gains. Sequential SG&A declines are anticipated but not yet realized in the income statement, with cost-cutting decisions from late Q4 and early 2026 not expected to meaningfully impact results until Q2, meaning near-term expense levels remain elevated relative to revenue growth. The strategic alternatives process, while presented as a potential upside, introduces significant uncertainty and distraction, with no assurance of outcome and potential for value-destructive outcomes if management pursues dilutive transactions or overpays for acquisitions amid pressure to show progress. Finally, the company’s guidance assumes profitability improvement in the second half of 2026, but this depends on multiple uncertain variables—fuel price stabilization, labor market normalization, timely receivables collections, and successful execution of cost-saving initiatives—any of which could fail to materialize, leaving DocGo structurally unprofitable despite revenue expansion.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Care Facilities

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HCA	HCA Healthcare, Inc.	87.94 Bn	11.25	1.15	48.02 Bn
2	CHE	Chemed Corp	18.08 Bn	51.68	7.12	0.09 Bn
3	THC	Tenet Healthcare Corp	16.59 Bn	9.74	0.77	13.21 Bn
4	DVA	Davita Inc.	15.37 Bn	14.02	1.10	10.63 Bn
5	EHC	Encompass Health Corp	10.07 Bn	654.20	1.66	2.57 Bn
6	ENSG	Ensign Group, Inc	9.52 Bn	27.18	1.81	0.14 Bn
7	UHS	Universal Health Services Inc	9.19 Bn	6.05	0.52	4.71 Bn
8	PACS	PACS Group, Inc.	6.96 Bn	28.55	1.28	0.05 Bn

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password